Biocept Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017 - 2011
Net Income	-32.09	-2.82	-17.81	-25.26	-25.21	Upgrade
Depreciation & Amortization	2.2	2.64	1	0.77	0.8	Upgrade
Share-Based Compensation	3.23	2.46	0.94	0.87	0.62	Upgrade
Other Operating Activities	13.38	1.42	-3.92	0.45	0.79	Upgrade
Operating Cash Flow	-13.29	3.69	-19.79	-23.05	-22.36	Upgrade
Capital Expenditures	-0.81	-1.57	-0.87	-0.74	-0.15	Upgrade
Investing Cash Flow	-0.81	-1.57	-0.87	-0.74	-0.15	Upgrade
Share Issuance / Repurchase	0.24	14.15	26.6	28.26	25.69	Upgrade
Debt Issued / Paid	-2.11	-1.77	-1.54	-0.93	-1.92	Upgrade
Other Financing Activities	-	-	0.66	2.34	-	Upgrade
Financing Cash Flow	-1.87	12.38	25.72	29.66	23.78	Upgrade
Net Cash Flow	-15.97	14.5	5.07	5.88	1.28	Upgrade
Free Cash Flow	-14.1	2.12	-20.65	-23.78	-22.5	Upgrade
Free Cash Flow Margin	-54.51%	3.46%	-75.21%	-430.21%	-692.26%	Upgrade
Free Cash Flow Per Share	-24.94	4.30	-52.31	-345.36	-2412.28	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).